Fostemsavir Tromethamine Drug Due Diligence Report 2026

This Fostemsavir Tromethamine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fostemsavir Tromethamine can convert its Small molecule drug profile and HIV envelope protein gp120 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fostemsavir Tromethamine (query alias: fostemsavir)
Modality / target	Small molecule drug; HIV envelope protein gp120; HIV envelope protein gp120 inhibitors
Highest global status	Approved
Originator	Bristol Myers Squibb Co.
Active developers	ViiV Healthcare Ltd., ViiV Healthcare BV, ViiV Healthcare Srl

The MCP disease footprint includes HIV Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05220358	Phase 4	Active, not recruiting	25	Mean and median change in CD4+T-cell count
NCT07393659	Phase 3	Not yet recruiting	183	Number of participants who discontinue the study intervention and the reason for discontinuation
NCT07030920	Phase 2	Recruiting	150	Change in total uncalcified plaque volume between baseline and month 24

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study

Phase 3; n=272; evaluation: Positive. Reported fields: CD4+/CD8+(week 96) = mean increase, +0.24, CD4+/CD8+ ratio ≥0.45 increased from 9% (25/272) at baseline to 40% (85/213) at week 96.

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

Phase 3; n=371; evaluation: Positive. Reported fields: Adverse Event: adverse events = COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident. Four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm^3) ; Adverse Event: adverse events = COVID-19-related events occurred in 25 out of 371 participants; all resolved without incident. Four participants discontinued for adverse events, one additional participant experienced a drug-related serious adverse event, and six deaths occurred (median last available CD4+ T-cell count, 3 cells/mm^3)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.

Phase 3; n=371; evaluation: Positive. Reported fields: Virologic suppression = 37 % ; Virologic suppression = 60 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fostemsavir Tromethamine addresses HIV Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2015-12-18	BMS Will Divest Its HIV R&D Portfolio to ViiV	Phase 3	US$350.0M upfront; US$1,105.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for estimation of fostemsavir using RP-UPLC in pharmaceutical dosage form and uses thereof”. The milestone feed surfaced a patent-application signal described as “Process for preparing fostemsavir”. The milestone feed surfaced a patent-application signal described as “Fostemsavir for use in heavily treatment-experienced HIV-1 infected individuals”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO